Three years after being merged with QLT the Aegerion business is to be sold out of bankruptcy protection.
By taking out Abide Therapeutics, Lundbeck has bought one of very few clinical-stage Tourette’s syndrome candidates.
Novartis will need to boost Xiidra sales to justify the hefty price it has paid, but the Swiss company has form.
A poor quarter is followed by an acquisition, but is it big enough?
Acelity falls to 3M, but the conglomerate has taken on a great deal of debt and could see its credit rating fall.
Using EvaluatePharma data, Vantage has described how big pharma R&D spending has shifted, showed how internally discovered novel medicines account for a growing…
An analysis of recent US drug sales confirms the growing role of licensing and acquisitions, though the biggest sellers conceal some interesting nuance.
Perhaps sensing trouble ahead Kiadis diversifies beyond ATIR101 by buying Cytosen, but it is a scientific appointment that will cause real excitement.
Bristol-Myers Squibb’s $74bn bid for Celgene led to a huge quarter, but a drop in the deal count could give pause to those hoping for a bumper year.